At the same time, with the use of routine immune indices, such as immunohistochemical markers CD10 and BCL2, the combination of LMO2-negative and CD38-positive results can be directly applied to the routine assessment of BL in clinical practice. This evidence concerns the gene BCL2 and Burkitt lymphoma.